Navigation Links
Apieron, Inc. Begins Customer Shipments of the Insight(TM) eNO System
Date:5/1/2008

Insight Measures Exhaled Nitric Oxide for More Targeted Asthma Control

MENLO PARK, Calif., May 1 /PRNewswire/ -- Apieron, Inc. (http://www.apieron.com) announced today that it has begun shipments of its Insight(TM) eNO System. Cleared by the FDA in March 2008, the Insight eNO System combines the accuracy, speed, and ease-of-use needed for the healthcare professional to provide office-based measurements of exhaled nitric oxide (eNO). Exhaled nitric oxide is a well established clinical indicator of airway inflammation and asthma control. With the use of eNO measurements, physicians can adjust inhaled corticosteroid therapy to optimize asthma control and avoid exacerbations or 'asthma attacks'.

The Insight eNO System's proprietary biosensor technology accurately measures eNO in parts per billion. Its single-use breath tubes are designed to be hygienic and convenient for the patient, and the disposable sensor generates a reading in less than a minute. Patient data can be stored and maintained in a unique format for trend analysis and printed for insurers' and patients' files. All of the System's functions are accessible through a small desktop monitor with a large color display and clinician-friendly interface.

"We showcased the Insight System at the March meeting of the American Academy of Allergy, Asthma and Immunology, and physicians responded enthusiastically to its graphical interface and its elegant technology," said Rich Lotti, President and CEO of Apieron, Inc. "As current methods for monitoring asthma airway inflammation are subjective, the Insight eNO System provides quantifiable information to increase therapeutic compliance. We believe this product will enable physicians to optimize medical therapy on an individualized basis, and therefore improve the standard of care for patients with asthma."

Sales and distribution of the Insight eNO System have been initiated with the introduction of an Apieron National Direct Sales Force in targeted major metropolitan regions.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was funded in 2003 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes such as eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.

Refer Questions to:

Holly McGarraugh

Apieron, Inc.

650-454-8101


'/>"/>
SOURCE Apieron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology:
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... ... autism conference held annually in this country. The AutismOne 2016 Conference, which is being ... the truth they often won’t hear elsewhere about helpful interventions and causes of chronic ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King Kullen! ... assortments and packaging. This staple for Valentine’s Day is a must-have, and can be ... Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, elegantly ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):